{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:41:36Z","timestamp":1789526496605,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.clinthera.2021.04.020","type":"journal-article","created":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T23:43:01Z","timestamp":1625960581000},"page":"1228-1244.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Health-Related Quality of Life Among Patients With HR+\/HER2\u2013 Early Breast Cancer"],"prefix":"10.1016","volume":"43","author":[{"given":"Carmen","family":"Criscitiello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Spurden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Piercy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhys","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debanjali","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Corsaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha K.","family":"Kurosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest H.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.04.020_bib0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0002","doi-asserted-by":"crossref","unstructured":"Hortobagyi, G.N., Connolly, J.L., D'Orsi, C.J., Edge, S.B., Mittendorf, E.A., Rugo, H.S., Solin, L.J., Weaver, D.L., Winchester, D.J., Giuliano, A., 2017. Breast, in: Amin, M.B., Edge, S.B., Greene, F.L., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., Sullivan, D.C., Jessup, J.M., Brierley, J.D., Gaspar, L.E., Schilsky, R.L., Balch, C.M., Winchester, D.P., Asare, E.A., Madera, M., Gress, D.M., Meyer, L.R. (Eds.), AJCC Cancer Staging Manual. Springer International Publishing, Cham, pp. 589\u2013636. https:\/\/doi.org\/10.1007\/978-3-319-40618-3_48.","DOI":"10.1007\/978-3-319-40618-3_48"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0003","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1200\/EDBK_201313","article-title":"New and important changes in the TNM staging system for breast cancer","volume":"38","author":"Hortobagyi","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170069","article-title":"Breast cancer subtype of French women is not influenced by socioeconomic status: A population-based-study","volume":"12","author":"Auguste","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0005","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2559.2008.02966.x","article-title":"Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa","volume":"52","author":"Awadelkarim","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0006","first-page":"438","article-title":"Breast cancer statistics, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0007","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl. Cancer Inst"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0008","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ygyno.2013.05.039","article-title":"Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study","volume":"130","author":"Puig-Vives","year":"2013","journal-title":"Gynecologic Oncology"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0009","first-page":"409","article-title":"Quality of life (QOL) and symptom burden (SB) in patients with breast cancer","volume":"25","author":"Hamer","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0010","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0011","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clinthera.2021.04.020_bib0012","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.8604","article-title":"Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update","author":"Denduluri","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0013","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2016.67.0182","volume":"34","author":"Denduluri","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0014","series-title":"Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims [WWW Document]","year":"2020"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0015","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/jama.2014.11100","article-title":"The PCORI perspective on patient-centered outcomes research","volume":"312","author":"Frank","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0016","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S1470-2045(16)30113-9","article-title":"New European guidance on patient-reported outcomes","volume":"17","author":"Venkatesan","year":"2016","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0017","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/PROM.S195296","article-title":"Are patient-reported outcomes useful in post-treatment follow-up care for women with early breast cancer? A scoping review","volume":"10","author":"Riis","year":"2019","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0018","first-page":"549","article-title":"Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications","volume":"25","author":"Stefanovic","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0019","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jpainsymman.2011.05.005","article-title":"Quality of life and experience of care in women with metastatic breast cancer: a cross-sectional survey","volume":"43","author":"Reed","year":"2012","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0020","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1089\/jpm.2016.0027","article-title":"Quality of life, mood, and prognostic understanding in patients with metastatic breast cancer","volume":"19","author":"Shin","year":"2016","journal-title":"J Palliat Med"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0021","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.clinthera.2017.07.009","article-title":"Patient-reported quality of life and treatment satisfaction in patients with HR+\/HER2- advanced\/metastatic breast cancer","volume":"39","author":"Wood","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000227","article-title":"Patient-reported pain severity, pain interference and health status in HR+\/HER2- advanced\/metastatic breast cancer","volume":"2","author":"Wood","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0023","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1002\/cncr.32757","article-title":"Health-related quality of life among breast cancer survivors and noncancer controls over 10 years: Pink SWAN","volume":"126","author":"Avis","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0024","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s11136-019-02127-7","article-title":"Diversity in changes of HRQoL over a 1-year period after radiotherapy in Norwegian breast cancer patients: results of cluster analyses","volume":"28","author":"Lazarewicz","year":"2019","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0025","doi-asserted-by":"crossref","first-page":"e746","DOI":"10.1634\/theoncologist.2019-0647","article-title":"Real-world evidence in oncology: opportunities and limitations","volume":"25","author":"Di Maio","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0026","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: Disease-Specific Programmes\u2014a means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0027","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1997.15.3.974","article-title":"Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument","volume":"15","author":"Brady","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0028","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/0163278705275341","article-title":"General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G)","volume":"28","author":"Brucker","year":"2005","journal-title":"Eval Health Prof"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0029","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0030","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","article-title":"United States valuation of EQ-5D-5L health states using an international protocol","volume":"22","author":"Pickard","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0031","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s11136-015-1108-2","article-title":"Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D","volume":"25","author":"Shiroiwa","year":"2016","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0032","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40273-019-00876-4","article-title":"A French value set for the EQ-5D-5L","volume":"38","author":"Andrade","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0033","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40273-018-0615-8","article-title":"German value set for the EQ-5D-5L","volume":"36","author":"Ludwig","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0034","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jval.2017.10.023","article-title":"Handling data quality issues to estimate the Spanish EQ-5D-5L value set using a hybrid interval regression approach","volume":"21","author":"Ramos-Go\u00f1i","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0035","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0036","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Medical Care"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0037","series-title":"Position statement on use of the EQ-5D-5L value set for England [WWW Document]","year":"2019"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0038","article-title":"US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples","volume":"29","author":"Jiang","year":"2020","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0039","series-title":"Self-Reported Population Health: An International Perspective based on EQ-5D","author":"Szende","year":"2013"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0040","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10198-018-0955-5","article-title":"Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries","volume":"20","author":"Janssen","year":"2019","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0041","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11136-013-0498-2","article-title":"The quality of life questionnaire EQ-5D-5L: psychometric properties and normative values for the general German population","volume":"23","author":"Hinz","year":"2014","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph14040426","article-title":"Health-Related quality of life of the general German population in 2015: results from the EQ-5D-5L","volume":"14","author":"Huber","year":"2017","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0043","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s11136-018-1877-5","article-title":"Validity of the EQ-5D-5L and reference norms for the Spanish population","volume":"27","author":"Hernandez","year":"2018","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0044","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jclinepi.2008.01.006","article-title":"The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients","volume":"61","author":"Charlson","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0045","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jclinepi.2004.01.012","article-title":"A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale","volume":"57","author":"Eton","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0046","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1111\/bph.13643","article-title":"Trastuzumab cardiotoxicity: from clinical trials to experimental studies","volume":"174","author":"Nemeth","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0047","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10549-017-4173-0","article-title":"Health-related quality of life in Black breast cancer survivors with and without triple-negative breast cancer (TNBC)","volume":"163","author":"Vadaparampil","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0048","article-title":"American Cancer Society\/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline","author":"Runowicz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0049","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0050","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10549-019-05433-3","article-title":"The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors","volume":"178","author":"de Ligt","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0051","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4103\/0973-1482.183214","article-title":"Health-related quality of life: Impact of surgery and treatment modality in breast cancer","volume":"14","author":"Enien","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0052","first-page":"4035","article-title":"Quality of life and symptom burden in patients with metastatic breast cancer","volume":"24","author":"Ecclestone","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0053","doi-asserted-by":"crossref","DOI":"10.1186\/s12905-017-0387-x","article-title":"Quality of life of breast and cervical cancer survivors","volume":"17","author":"Huang","year":"2017","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0054","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s10549-019-05197-w","article-title":"Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project","volume":"175","author":"Marschner","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0055","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.breast.2017.08.008","article-title":"Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry","volume":"37","author":"M\u00fcller","year":"2018","journal-title":"The Breast"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0056","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0057","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2015.64.8675","article-title":"Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the Suppression of Ovarian Function Trial","author":"Ribi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0058","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/cncr.11745","volume":"98","author":"Baum","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0059","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-006-9260-6","article-title":"Quality of life of postmenopausal women in the ATAC (\u201cArimidex\u201d, tamoxifen, alone or in combination) trial after completion of 5 years\u2019 adjuvant treatment for early breast cancer","volume":"100","author":"Cella","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2021.04.020_bib0060","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial","volume":"359","year":"2002","journal-title":"The Lancet"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821002162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821002162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:54:00Z","timestamp":1758963240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821002162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0149291821002162"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.04.020","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-Related Quality of Life Among Patients With HR+\/HER2\u2013 Early Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}